RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · SPECIFICATIONS AND PRICES REQUIRE FINAL CONFIRMATION Learn more
Research Library

PEPTIDES BIO / QUALITY & DOCUMENTATION

TB-500 and Thymosin Beta-4: Nomenclature, Source Scope and Documentation Review

A research-use-only review of TB-500 and Thymosin beta-4 naming boundaries, a defined actin source, and separate batch documentation.

Published Updated Published byPeptides Bio

Research or raw-material evaluation only. Not for human or veterinary use.

TB-500 and full-length thymosin beta-4 should not be treated as interchangeable names for one experiment. Published analytical work identified a shorter acetylated peptide, Ac-LKKTETQ, in material labelled TB-500, while a separate thymosin beta-4 paper measured how the full-length peptide interacts with actin. This difference matters when selecting a 5 mg or 10 mg catalogue product and discussing the exact research material required.

TB-500 research diagram separating Ac-LKKTETQ analytical records, full-length thymosin beta-4 actin research and the catalogue TB-500 item
Check which molecule a paper measured before using its results to plan a material enquiry.

What the TB-500 analytical paper found

A 2012 analytical study used high-performance liquid chromatography and high-resolution mass spectrometry to identify N-terminal acetylated LKKTETQ (Ac-LKKTETQ) in a product described as TB-500. It also outlined detection approaches for that sequence in study matrices. This is a concrete identity and analytical-method result for the tested material, not a universal specification for every product using the TB-500 name. Read the original analytical record.

A later study of sequence-defined Ac-LKKTETQ used mass spectrometry to follow metabolites in experimental systems. It reported Ac-LK as a major metabolite in rats over the first 0–6 hours and detected Ac-LKK up to 72 hours; in the authors’ fibroblast assay, only the tested Ac-LKKTE metabolite showed a significant wound-closure signal versus control. These results help separate a parent peptide, its metabolites and the assay endpoint. Read the analytical and cell-assay study.

Where full-length thymosin beta-4 fits

A different in-vitro paper tested full-length thymosin beta-4 with actin. Below 20 µM, the authors described G-actin sequestration; at higher tested concentrations they observed additional F-actin interactions. That is useful background for thymosin beta-4 research, but it does not identify the sequence or reproduce the activity of a separately labelled TB-500 material. Read the actin experiment.

TB-500 catalogue choices

The site lists TB-500 5 mg and TB-500 10 mg research-material formats; the 10 mg listing links to a product COA. For a quotation or analytical discussion, send the format you need and the exact molecular identity or method relevant to your project. A catalogue label and a paper’s tested sequence are connected only when the material record establishes that connection.

Contact the team for product availability, pricing and documentation. The cited analytical and in-vitro studies provide research context, not human-use guidance.

References

  1. Carlier et al., Thymosin beta-4 and actin assembly, PMID 8621582

Need a product record?

Build a structured request.

Browse materials